{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:06:50Z","timestamp":1784804810824,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.steroids.2014.05.023","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T20:10:25Z","timestamp":1402431025000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Use of endogenous cortisol 6\u03b2-hydroxylation clearance for phenotyping in vivo CYP3A activity in women after sequential administration of an oral contraceptive (OC) containing ethinylestradiol and levonorgestrel as weak CYP3A inhibitors"],"prefix":"10.1016","volume":"87","author":[{"given":"Hiromi","family":"Shibasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1403-1698","authenticated-orcid":false,"given":"Miyuki","family":"Kuroiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Uchikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Tsuboyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitomo","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyoko","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2014.05.023_b0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","article-title":"Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans","volume":"24","author":"Wilkinson","year":"1996","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.steroids.2014.05.023_b0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.0306-5251.2001.01521.x","article-title":"The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity","volume":"53","author":"Belle","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.steroids.2014.05.023_b0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","article-title":"Pharmacokinetic drug interactions involving 17\u03b1-ethinylestradiol. A new look at an old drug","volume":"46","author":"Zhang","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.steroids.2014.05.023_b0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/dmd.109.028746","article-title":"Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin","volume":"38","author":"Quinney","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.steroids.2014.05.023_b0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","article-title":"Mechanism of cytochrome P450-3A inhibition by ketoconazole","volume":"63","author":"Greenblatt","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.steroids.2014.05.023_b0030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0029-7844(01)01443-0","article-title":"Evaluation of interaction between fluconazole and an oral contraceptive in healthy women","volume":"98","author":"Hilbert","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.steroids.2014.05.023_b0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2125.2008.03132.x","article-title":"Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine\/zidovudine, and ethinyloestradiol\/levonorgestrel in healthy volunteers","volume":"65","author":"Abel","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.steroids.2014.05.023_b0040","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1176\/appi.psy.49.2.168","article-title":"Oral contraceptives","volume":"49","author":"Oesterheld","year":"2008","journal-title":"Psychosomatics"},{"key":"10.1016\/j.steroids.2014.05.023_b0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00228-009-0648-1","article-title":"Evaluation of drug\u2013drug interactions with fesoterodine","volume":"65","author":"Malhotra","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.steroids.2014.05.023_b0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1528-1157.1999.tb00779.x","article-title":"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women","volume":"40","author":"Fattore","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.steroids.2014.05.023_b0055","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0009-9236(96)80009-9","article-title":"Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics","volume":"59","author":"Slayter","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.steroids.2014.05.023_b0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s002280050543","article-title":"Can oral contraceptive steroids influence the elimination of nifedipine and its primary pyridine metabolite in humans?","volume":"54","author":"Balogh","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.steroids.2014.05.023_b0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.2000.00271.x","article-title":"Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A activity as measured by midazolam 1\u2032-hydroxylation","volume":"50","author":"Palovaara","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.steroids.2014.05.023_b0070","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zohu","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.steroids.2014.05.023_b0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008571-199408000-00001","article-title":"Noninvasive tests of CYP3A enzymes","volume":"4","author":"Watkins","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.steroids.2014.05.023_b0080","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","article-title":"Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes","volume":"10","author":"Streetman","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.steroids.2014.05.023_b0085","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1021\/tx00016a015","article-title":"Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene","volume":"3","author":"Guengerich","year":"1990","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.steroids.2014.05.023_b0090","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0960-0760(91)90129-S","article-title":"Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestraiol and other substrates by human liver microsomes","volume":"38","author":"Back","year":"1991","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2014.05.023_b0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1034\/j.1600-0773.2003.t01-1-930202_93_2.x","article-title":"A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes","volume":"93","author":"Laine","year":"2003","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.steroids.2014.05.023_b0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0960-0760(95)00158-V","article-title":"Urinary excretion of 6\u03b2-hydroxycortisol in women during treatment with different oral contraceptive formulations","volume":"55","author":"Kuhnz","year":"1995","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2014.05.023_b0105","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/00912700122010627","article-title":"Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan","volume":"41","author":"McCune","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.steroids.2014.05.023_b0110","first-page":"S98","article-title":"Urinary 6\u03b2-hydroxycortisol\/cortisol ratio does not reflect in vivo CYP3A activity in humans","volume":"16","author":"Furuta","year":"2001","journal-title":"Xenobio Metab Dispos"},{"key":"10.1016\/j.steroids.2014.05.023_b0115","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1124\/dmd.31.11.1283","article-title":"Evidence for the validity of cortisol 6\u03b2-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans","volume":"31","author":"Furuta","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.steroids.2014.05.023_b0120","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/clpt.2011.53","article-title":"Evaluation of 6\u03b2-hydroxycortisol, 6\u03b2-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo","volume":"89","author":"Peng","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.steroids.2014.05.023_b0125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0039-128X(99)00102-6","article-title":"Synthesis of multi-labeled cortisols and cortisones with 2H and 13C for study of cortisol metabolism in humans","volume":"65","author":"Furuta","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2014.05.023_b0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jchromb.2003.11.001","article-title":"Simultaneous determination of 6\u03b2-hydroxycortisol and cortisol in human urine by liquid chromatography with ultraviolet absorbance detection for phenotyping the CYP3A activity determined by the cortisol 6\u03b2-hydroxylation clearance","volume":"801","author":"Furuta","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.steroids.2014.05.023_b0135","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1007\/s00216-012-5714-3","article-title":"Separation and quantitative determination of 6\u03b1-hydroxycortisol and 6\u03b2-hydroxycortisol in human urine by high-performance liquid chromatography with ultraviolet absorption detection","volume":"402","author":"Shibasaki","year":"2012","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.steroids.2014.05.023_b0140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-4347(99)00496-X","article-title":"Simultaneous determination of endogenous and 13C-labelled cortisols and cortisones in human plasma by stable isotope dilution mass spectrometry","volume":"738","author":"Furuta","year":"2000","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.steroids.2014.05.023_b0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0090-9556(25)07244-7","article-title":"Pharmacokinetics of stable isotopically labeled l-histidine in humans and the assessment of in vivo histidine ammonia lyase activities","volume":"24","author":"Furuta","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.steroids.2014.05.023_b0150","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","article-title":"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin","volume":"64","author":"Gorski","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.steroids.2014.05.023_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.105.004747","article-title":"Mechanism-based inactivation and reversibility: Is there a new trend in the inactivation of cytochrome P450 enzymes?","volume":"34","author":"Blobaum","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.steroids.2014.05.023_b0160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0163-7258(89)90010-7","article-title":"Nifedipine: variability in its kinetics and metabolism in man","volume":"44","author":"Breimer","year":"1989","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.steroids.2014.05.023_b0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0163-7258(87)90051-9","article-title":"The urinary 6\u03b2-hydroxycortisol excretion in man on inducers and inhibitors of the hepatic mixed function oxidase","volume":"33","author":"Desager","year":"1987","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.steroids.2014.05.023_b0170","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0091-6749(80)90004-4","article-title":"The effect of troleandomycin on methylprednisolone elimination","volume":"66","author":"Szefler","year":"1980","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.steroids.2014.05.023_b0175","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1211\/0022357991776697","article-title":"High-performance liquid-chromatographic-atmospheric-pressure chemical-ionization ion-trap mass-spectrometric identification of isomeric C6-hydroxy and C20-hydroxy metabolites of methylprednisolone in the urine of patients receiving high-dose pulse therapy","volume":"51","author":"Vree","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.steroids.2014.05.023_b0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/dmd.112.048561","article-title":"Intraindividual and interindividual variabilities in endogenous cortisol 6\u03b2-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans","volume":"41","author":"Shibasaki","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.steroids.2014.05.023_b0185","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.steroids.2014.05.023_b0190","first-page":"2553","article-title":"Phase I study of LOC-31 \u2013 Single and multiple oral administration \u2013 Rinsyoiyaku","volume":"12","author":"Ochiai","year":"1990","journal-title":"J Clin Ther Med"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T09:11:03Z","timestamp":1746263463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X14001366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":38,"alternative-id":["S0039128X14001366"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2014.05.023","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of endogenous cortisol 6\u03b2-hydroxylation clearance for phenotyping in vivo CYP3A activity in women after sequential administration of an oral contraceptive (OC) containing ethinylestradiol and levonorgestrel as weak CYP3A inhibitors","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2014.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}